Prosecution Insights
Last updated: November 04, 2026

Shanghai Hengrui Pharmaceuticals Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Shanghai Hengrui Pharmaceuticals Co. Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. This involves a distinct examiner and a single art unit. The focus on biotechnology suggests that the company's current intellectual property efforts are directed toward complex biological or pharmaceutical developments.

DONOGHUE, BRITTNEY ERIN is the busiest examiner for this portfolio. This examiner is managing 1 busiest examiner pending office action, which constitutes the entire pending workload for the company. A centralized prosecution structure like this one provides the benefit of consistent feedback from the USPTO, as all concerns originate from a single source.

For the practitioner, the primary challenge is to address the specific technical requirements of the assigned examiner and art unit. The alignment of the technology area with the art unit indicates that the application is being reviewed by specialists in the biotech sector. Effective prosecution will require a detailed understanding of the examiner's previous actions and the specific legal standards applied within this art unit.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
DONOGHUE, BRITTNEY ERIN 1 59.0% +47.6%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18039604 ANTI-TSLP ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF DONOGHUE, BRITTNEY ERIN —

Top Art Units

Art UnitApps
1675 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18039604 ANTI-TSLP ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF DONOGHUE, BRITTNEY ERIN 1675 §103DPOther Non-Final OA — Pending May 31, 2023

Managing Shanghai Hengrui Pharmaceuticals Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Shanghai Hengrui Pharmaceuticals Co. Ltd. have?

Shanghai Hengrui Pharmaceuticals Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Shanghai Hengrui Pharmaceuticals Co. Ltd. applications?

Brittney Erin Donoghue has the most, with 1 of Shanghai Hengrui Pharmaceuticals Co. Ltd.'s pending office actions.

What technology area are Shanghai Hengrui Pharmaceuticals Co. Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month